LifeSci Advisors provides life science companies comprehensive solutions to communications and investor outreach.
Talem Therapeutics has advanced development of candidate panel TATX-112, against an undisclosed target, into formal lead candidate characterization.
23-H7 binds to all tested variants of concern and blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action
Increase in gross profit and expansion in research and development initiatives
The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy
Management to provide update on emerging SARS-CoV-2 variants of concern.